CEMIG (NYSE:CIG) and Biotricity (OTCMKTS:BTCY) are both utilities companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
This is a breakdown of recent recommendations and price targets for CEMIG and Biotricity, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk and Volatility
CEMIG has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 4.48, indicating that its share price is 348% more volatile than the S&P 500.
This table compares CEMIG and Biotricity’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares CEMIG and Biotricity’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CEMIG||$5.91 billion||0.73||$476.61 million||N/A||N/A|
CEMIG has higher revenue and earnings than Biotricity.
Institutional and Insider Ownership
1.9% of CEMIG shares are held by institutional investors. Comparatively, 0.0% of Biotricity shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CEMIG pays an annual dividend of $0.09 per share and has a dividend yield of 3.1%. Biotricity does not pay a dividend.
CEMIG beats Biotricity on 7 of the 8 factors compared between the two stocks.
Companhia Energética de Minas Gerais, through its subsidiaries, engages in the generation, transmission, distribution, and sale of electricity in Brazil. The company generates electricity through renewable energy sources, such as water, wind, sun, and biomass; or non-renewable sources, including fossil and nuclear fuels. As of December 31, 2016, it operated hydroelectric plants, thermoelectric plants, and solar plants with a total installed capacity of approximately 8,000 megawatts in 10 states of Brazil. It is also involved in the telecommunications and energy solutions consulting businesses; exploitation of natural gas; sale and trading of electricity; and acquisition, transport, and distribution of gas and its subproducts and derivatives, as well as provision of technology systems and systems for operational management of public service concessions, including companies operating in electricity, gas, water and sewerage, and other utility companies. The company was founded in 1952 and is headquartered in Belo Horizonte, Brazil.
Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, focuses on providing biometric data monitoring solutions in the United States. The company focuses to deliver remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It is developing Bioflux mobile cardiac telemetry solution that provides recurring reimbursements to doctors, hospitals, and independent diagnostic testing facilities; revenue model that fits within the established insurance billing practices; built-in cellular connectivity; and motion tracking to detect exercise, activity, and disorientation. The company is also developing Biolife, a health and lifestyle solution for individuals. It has a collaboration agreement with the University of Calgary to determine the predictive value of electrocardiogram readings in preventative healthcare applications. Biotricity, Inc. is based in Redwood City, California.
Receive News & Ratings for CEMIG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEMIG and related companies with MarketBeat.com's FREE daily email newsletter.